Beta-thalassaemia intermedia : evaluation of endocrine and bone complications by M. Baldini et al.
Research Article
Beta-Thalassaemia Intermedia: Evaluation of Endocrine and
Bone Complications
M. Baldini,1 A. Marcon,1 R. Cassin,2 F. M. Ulivieri,3
D. Spinelli,2 M. D. Cappellini,1,2 and G. Graziadei1
1 Rare Diseases Center, Department of Medicine and Medical Specialities,
Ca’ Granda Foundation IRCCS Ospedale Maggiore Policlinico, 20122 Milan, Italy
2 Department of Clinical Sciences and Community Health, University of Milan, Via F. Sforza, 20122 Milan, Italy
3 Nuclear Medicine, Bone Metabolic Unit, Ca’ Granda Foundation IRCCS Ospedale Maggiore Policlinico, 20122 Milan, Italy
Correspondence should be addressed to G. Graziadei; giovanna.graziadei@policlinico.mi.it
Received 4 April 2014; Revised 11 June 2014; Accepted 16 June 2014; Published 7 July 2014
Academic Editor: Paolo Ricchi
Copyright © 2014 M. Baldini et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. Data about endocrine and bone disease in nontransfusion-dependent thalassaemia (NTDT) is scanty. The aim of our
study was to evaluate these complications in 𝛽-TI adult patients.Methods. We studied retrospectively 70 𝛽-TI patients with mean
followup of 20 years. Data recorded included age, gender, haemoglobin and ferritin levels, biochemical and endocrine tests, liver
iron concentration (LIC) from 𝑇2∗, transfusion regimen, iron chelation, hydroxyurea, splenectomy, and bone mineralization by
dual X-ray absorptiometry.Results.Thirty-seven (53%)males and 33 (47%) females were studied, withmean age 41±12 years, mean
haemoglobin 9.2 ± 1.5 g/dL, median ferritin 537 (range 14–4893), and mean LIC 7.6 ± 6.4mgFe/g dw. Thirty-three patients (47%)
had been transfused, occasionally (24/33; 73%) or regularly (9/33; 27%); 37/70 (53%) had never been transfused; 34/70 patients had
been splenectomized (49%); 39 (56%) were on chelation therapy; and 11 (16%) were on hydroxyurea. Endocrinopathies were found
in 15 patients (21%): 10 hypothyroidism, 3 hypogonadism, 2 impaired glucose tolerance (IGT), and one diabetes. Bone disease was
observed in 53/70 (76%) patients, osteoporosis in 26/53 (49%), and osteopenia in 27/53 (51%). Discussion and Conclusions. Bone
disease was found in most patients in our study, while endocrinopathies were highly uncommon, especially hypogonadism. We
speculate that low iron burden may protect against endocrinopathy development.
1. Introduction
Beta-thalassaemia intermedia (𝛽-TI) is a form of NTDT en-
compassing patients who do not require regular transfusions
throughout life, although they may be needed occasionally
or even frequently in certain clinical conditions [1, 2]. These
patients spontaneously maintain Hb levels 7–10 g/dL and
show different levels of splenomegaly and iron overload.
Beta-TI patients show clinical pictures of intermediate
severity between the asymptomatic carrier (Thalassaemia
Minor) and the transfusion-dependent thalassaemia patients
(Thalassaemia Major). The association of mild, moderate,
and severe 𝛽-mutations as well as association of triplica-
tion/multiplication of 𝛼-globin genes can be responsible
for wide spectrum of genotypes, and a genotype/phenotype
correlation has been observed.
However, several genetic as well as environmental factors
can modify clinical expression. The genes affecting the
globin chain production are recognized as primary and
secondary modifiers, but several other conditions, called
tertiary modifiers, can affect the clinical expression, such
as the coinheritance of hereditary haemochromatosis or
Gilbert syndrome, or alterations of genes involved in iron
absorption, bone metabolism, or susceptibility to infections
[3]. There is increasing evidence that bone disease may be
modified by polymorphisms at loci that are involved in bone
metabolism, including the genes for the vitamin D receptor,
collagen, and the oestrogen receptor [4–7].Moreover, varying
availability of medical care can influence the outcome of 𝛽-TI
patients.
Endocrine complications are less commonly seen in
patients with NTDT than in those with more severe forms
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of thalassemia (𝛽-TM and/or severe forms of haemoglobin
E/𝛽-thalassaemia) [1, 8–12].
Nonetheless, 𝛽-TI patients remain at risk of morbidity
from endocrine gland and bone pathology, associated with
bone pain and fractures [3]. An increased risk of devel-
oping several complications, including diabetes mellitus,
hypothyroidism, hypoparathyroidism, hypogonadism, and
osteoporosis, has been reported in association with higher
liver iron concentration (LIC) values or serum ferritin levels
as the patients advance in age [13–17]. Conversely, from
observational studies lower rates of the samemorbiditieswere
associated with iron chelation therapy [11].
As in patients with 𝛽-TM [18], the pathophysiology of
endocrinopathies and low bone mineral density in patients
with 𝛽-TI is probably multifactorial; ineffective erythro-
poiesis and expansion of the erythron in the bone marrow
are directly implicated [1, 19, 20] as well as low foetal
haemoglobin, splenectomy, and hydroxyurea therapy [14, 19,
21].
In view of the limited data on endocrinopathy and bone
disease prevalence in NTDT, we evaluated these complica-
tions in a group of 𝛽-TI adult patients.
2. Patients and Methods
In a retrospective study, 70 𝛽-TI adult patients with a mean
followup of 20 years were investigated. All patients were
followed up at the Hereditary Anaemia Centre of Fondazione
IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milan.
The study was in adherence to the tenets of the Declaration
of Helsinki and approval from the local ethics committee was
obtained.
Disease history and systemic treatment, if any, were
recorded for all patients including age, gender, haemoglobin
and ferritin levels, biochemical and endocrine tests, bone
metabolism indices, transfusion regimen, chelation, hydrox-
yurea therapy, bone specific treatment, and splenectomy.
Patients were considered occasionally transfused when
the number of transfusions was <6 per year.
Liver iron concentration (LIC) was derived from T2∗
from magnetic resonance imaging (Scanner MRI 1,5 Tesla
Avanto Siemens, Enlargen - software CMR Tools, Imperial
College, London) according to the formula [1/(T2∗/1000)] ×
0.0254 + 0.202 [21].
All patients underwent bone densitometry scan per-
formed by dual X-ray photon absorptiometry (Hologic Bone
Densitometer QDR Discovery A, Version 12.7.3.1 WAL-
THAM, MA, USA) at the lumbar spine and femur. The
bone mineral density values were expressed as 𝑇- and 𝑍-
scores; the 𝑇-score was calculated as a standard deviation
score (SDS) from a normal reference population database,
while the 𝑍-score was calculated as an SDS from an age-
and sex-matched population. Data were classified according
to the WHO report (WHO Technical Report, ISCD Official
Position Paper 2007): 𝑇-score > −1: normal, 𝑇-score between
−1 and −2.5: low bone density (osteopenia), and 𝑇-score <
−2.5: osteoporosis.
Data are presented as means and standard deviation or
median and range as appropriate.
3. Results
Among 70 patients, 37 (53%) were males and 33 (47%) were
females;mean agewas 41±12 years andmean of haemoglobin
levels was 9.2 ± 1.5 g/dL. Median ferritin was 537 (range
14–4893) ng/mL and mean LIC 7.6 ± 6.4mgFe/g dw. Eleven
patients (16%) were anti-HCV antibody positive, and among
them 6 (55%) were HCV-RNA positive. Splenectomy had
been performed in 34 out of 70 patients (49%) and 13 patients
(18%) had a history of bone fractures (2 spontaneous and 11
following traumas).
Regarding patient treatment, 37/70 (53%) had never been
transfused and 33 (47%) had been occasionally (24/33; 73%)
or regularly (9/33; 27%) transfused. The patients in the latter
group were considered NTDT patients because of the regular
transfusion regimen that did not start in childhood but starts
later, after an occasional event (pregnancy, surgery, infection,
. . .), or because of clinical complications, such as heart failure
and fatigue with very low Hb levels leading to poor quality of
life. Moreover, the mean transfusional range was 40 days.
Thirty-nine patients (56%) were on chelation therapy and
11 (16%) on hydroxyurea. Hormone defects were corrected
with replacement therapy in all cases except one, due to
clinical contraindications to sex steroid treatment. Four
patients (6%) were on bisphosphonate, 5 (7%) on calcium +
vitamin D supplementation, 2 (3%) on calcium alone, and 16
(23%) on vitamin D alone.
Characteristics of the population are summarized in
Table 1.
Only 15 out of 70 patients (21%) were diagnosed with
endocrinopathy: 10 had hypothyroidism (5 of them were
subclinical and did not require therapy), 3 hypogonadism, 2
impaired glucose tolerance (IGT), and one diabetes. Among
them, only one patient presented two endocrine compli-
cations associated (hypogonadism and diabetes). None of
the patients presented with hypoparathyroidism. Vitamin D
deficiency was present in 49 patients (70%).
Bone disease was observed in 53 (76%) patients, osteo-
porosis in 26, and osteopenia in 27 𝛽-TI (Table 2).
In the group of patients with osteoporosis, 7 of them
(10%) had involvement of both vertebral and femoral sites,
18 (26%) presented only vertebral osteoporosis, and one
patient (1%) only had femoral osteoporosis. In the group of
patients with osteopenia, 15 (21%) had involvement of both
sites; 8 (11%) only had involvement of the vertebral site and
4 (6%) only had involvement of the femoral site. Among
the 5 patients with selective involvement of the femoral site
(cortical bone disease), BMDwas reduced both at the femoral
neck and at total femoral scan.
4. Discussion
Endocrine data in 𝛽-TI patients is scanty in the literature.The
biggest problem with 𝛽-TI patients is the wide heterogeneity
of the genotypes and of clinical picture, covering a broad
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Table 1: Characteristics of the population.
Parameter Values
Male (number (%)) 37/70 (53)
Female (number (%)) 33/70 (47)
Age (years ± SD) 41 ± 12
Hb (g/dL ± SD) 9.2 ± 1.5
Ferritin (ng/mL (range)) 537∗ (14–4893)
LIC (mg Fe/g dw ± SD) 7.6 ± 6.4
Anti-HCV positive (number (%)) 11/70 (16)
HCV-RNA positive (number (%)) 6/11 (55)
Splenectomy (number (%)) 34/70 (49)
Transfusion therapy (number (%))
Never 37/70 (53)
Occasionally 24/70 (34)
Regularly 9/70 (13)
Chelation therapy (number (%)) 39/70 (56)
Hydroxyurea therapy (number (%)) 11/70 (16)
Hormone replacement therapy (number (%)) 2/70 (3)
Levothyroxine therapy (number (%)) 5/70 (7)
Bisphosphonate (number (%)) 4/70 (6)
Calcium + vitamin D (number (%)) 5/70 (7)
Calcium alone (number (%)) 2/70 (3)
Vitamin D alone (number (%)) 16/70 (23)
∗median and range.
Table 2: Osteopenia/osteoporosis in 70 𝛽-TI adult patients.
Osteoporosis 26/70
Vertebral 18/26
Femoral 1/26
Total 0
Neck 0
Both 1/1
Both 7/26
Total 1/7
Neck 2/7
Both 4/7
Osteopenia 27/70
Vertebral 8/27
Femoral 4/27
Total 0
Neck 0
Both 4/4
Both 15/27
Total 3/15
Neck 3/15
Both 9/15
Normal 17/70
spectrum from good general health even in adult age to a
compromised condition with early growth retardation and
skeletal deformities, due to intense ineffective erythropoiesis
and erythroid bone marrow hypertrophy [22, 23]. In such a
complex scenario, which also comprises differing genetic pat-
terns and organ damage, the identification of genetic and/or
clinical risk factors for endocrinopathy or osteoporosis is a
real challenge. Further, bone and endocrine state have been
less studied in 𝛽-TI than in 𝛽-TM patients.
In our patients with 𝛽-TI, the prevalence of endocrinopa-
thy does not appear significantly different from that expected
in the general nonthalassaemic population [24–26], while
bone demineralization, even severe, is a highly common find-
ing, affectingmore than two thirds of patients.Theprevalence
of osteopenia and osteoporosis is very similar, and trabecular
bone is predominantly involved regardless of bone disease
severity. These findings are in line with previous literature, as
bone abnormalities typical of 𝛽-TM have been described as
often present in 𝛽-TI, and sometimes more marked, starting
from the first decade of life. An increased risk of fractures,
even spontaneous or following minor traumas, has also been
reported; this has been ascribed to osteoporosis as well as
to medullary overgrowth due to erythroid stress, aiming to
compensate for anaemia [27]. When fractures are recurrent,
some authors recommend transfusion therapy [28]. In a large
thalassaemic population from North America, Vogiatzi et al.
described a 12% prevalence of fractures in 𝛽-TI patients,
increasing with age andwith use of sex hormone replacement
[29], that is, with hypogonadism.
An additional negative influence on bone condition can
be caused by the association between 𝛽-TI and 25-OH
vitamin D deficiency, frequently reported in thalassaemic
populations [12, 29]. In our group, vitamin D deficiency was
demonstrated in the majority of the 𝛽-TI patients, 35% of
whom were compliant with cholecalciferol supplementation
prescribed at the usually recommended dose of 800 IU/day
[30]. Nonetheless, bone demineralization of varying severity
and low 25OH-vitamin D levels were present in most cases.
The persistence of inadequate vitamin D status despite sup-
plementation and the possibility of reduced skin production
or impaired liver metabolism of the vitamin have been pre-
viously described in 𝛽-TM patients [31, 32]. If 𝛽-TI patients
had similarly increased vitamin D requirements in order to
produce adequate 25-OH D serum levels, they would need
high dose supplementation, as indicated by Soliman et al.,
recommending repletion therapy with 50000 IU of vitamin
D weekly for 8 weeks, followed by maintenance with doses
up to 50000 IU per month [32].
Unlike 𝛽-TM, endocrinopathies play a minor role in
bone condition in 𝛽-TI. In a previous study from our group,
78.4% out of 111 𝛽-TM patients were hypogonadic, 17.1%
were hypoparathyroid, and 16.2%were both hypogonadic and
hypoparathyroid, while glucose metabolism was impaired in
40% of patients (diabetes mellitus in 18% and IGT in 22%)
[33]. Conversely, in our 𝛽-TI patients a single endocrine
defect was present in merely 15 out of 70 patients (21%), and
only one patient (0.01%) had more than one defect.
The low prevalence of endocrine complications in 𝛽-TI
has been previously described; however, in our patients the
prevalence of single defects differs from previous reports.
More precisely, hypogonadism was exceptional in our group;
there were no cases of verified infertility, and more than 50%
of our patients had offspring in all cases without induction. In
the literature, hypogonadism has been described as the most
common endocrine complication in 𝛽-TI patients, with pre-
dominant involvement of females [13, 34]. Moreover, puberty
has been described as not infrequently delayed and irregular
menses as not unusual, even if generally fertility appeared
not to be compromised, with spontaneous conception [35–
37]. Diabetes and hypothyroidism appear less common in the
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literature than hypogonadism; the Optimal Care study found
prevalence of 1.7%, 5.7%, and 17% for diabetes, hypothy-
roidism, and hypogonadism, respectively [13]. By contrast,
the thyroid was the most frequently affected gland among
our patients (10 cases, 14%), and 24% of them had antithyroid
antibodies positivity; this percentage is in line with the high
prevalence of autoimmune hypothyroidism in Italy [38]. The
prevalence of glucosemetabolism impairment in our patients
was similar to values described in the literature, while no
patient was affected by hypoparathyroidism.
It is well known that the different endocrine involvement
between 𝛽-TI and 𝛽-TM highlights the different impact
of iron overload on the two diseases. In effect, severe
iron-overload related endocrine dysfunction is universally
described in 𝛽-TM, while in 𝛽-TI the pattern of iron
overload is preferentially hepatic and it develops gradually
throughout life. Compared to the reported data in NTDT
[39], our 𝛽-TI patients showed a very low iron burden,
expressed as LIC (mean values 7.6mg Fe/g dw); this could
explain the low prevalence of endocrinopathies, especially
regarding the most iron-sensitive cells (gonadotrophs). On
the other hand, these LIC values in our series can be ascribed
to the nontransfusion-dependent status per se, considering
that >50% had never been transfused (mean Hb 9.8 g/dL),
and all were compliant with iron chelation therapy when
prescribed.This is in agreement with the reported association
between transfusion therapy (either intermittent or regular)
and increased risk of endocrinopathy [13]. In fact the 3
patients with hypogonadism in the present group all had high
LIC values and had been transfused.
A further important consideration is the good tissue oxy-
genation due to the satisfactoryHb levels in our patients, with
the mean Hb in the whole series being 9.2 g/dL (evaluating
pretransfusion values in regularly or occasionally transfused
patients).
Regarding bone mineralization, the group of trans-
fused (both regularly and occasionally) thalassaemic patients
showed lower BMD values compared to ones that were not
transfused. This finding suggests that when bone damage
is established, it persists despite transfusion therapy. In
fact, in the group of transfused patients haemoglobin levels
had been low for many years before starting transfusional
therapy.
We recognize that one limit of our study is the lack of
statistical analysis, but this is due to the low prevalence of
endocrinopathies, which does not allow any correlation to
be drawn. For example, it would be interesting to evaluate if
endocrine deficiency can be associated with splenectomy or
with hydroxyurea treatment, but this analysis would require
a larger population.
For the same reason, we did not divide patients into
groups according to transfusion status to avoid an excessive
fragmentation of the population.
In view of the scarcity of endocrinological and den-
sitometric data on the 𝛽-TI population in the literature,
unlike the well-studied 𝛽-TM patients, our findings warrant
further studies to evaluate the impact of transfusion and iron-
chelation therapy on the outcome of the patients.
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